Naratriptan Bei Migräne Ratiopharm (Naratriptan)

Naratriptan works by selectively activating serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This activation causes constriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and reducing pain.

The specific dose of naratriptan is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for naratriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Naratriptan belongs to the triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics. Compared with other triptans, naratriptan has a longer half‑life, offering sustained relief, but its onset of action may be slower than some newer agents.

Naratriptan tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and store out of reach of children.

Naratriptan is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the first sign of a migraine attack. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious risks include serotonin syndrome when combined with other serotonergic drugs, coronary vasospasm or myocardial ischemia in patients with cardiovascular disease, and rare severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, severe dizziness, or signs of an allergic reaction.

Naratriptan is contraindicated in individuals with uncontrolled hypertension, recent myocardial infarction, severe coronary artery disease, history of stroke or transient ischemic attack, and in patients taking MAO inhibitors or other triptans. It should also be avoided in anyone with known hypersensitivity to naratriptan or its excipients.